EWMA Patient Outcome Group

The EWMA Patient Outcome Group (POG) was created in 2008. Members of the group have a clinical scientific background, including both clinicians and representatives from companies working within wound healing.

The overall objective of the group is to address topics such as structure of treatment as well as the quality of traditional clinical trials and evidence in wound care. The group is concerned with the approval and reimbursement of wound care services including the regulation of patient access to high quality wound management.


 Primary objectives of the POG are to:

  • Identify barriers to implementation of evidence based guidelines in wound healing
  • Develop or identify guidelines for clinical investigations in wound care
  • Participate in the public debates and address policy making on pan-European and national level
  • Create and implement consensus (in collaboration with clinicians, companies, reimbursement authorities, European collaborative groups and institutions) on various aspects of wound management

Members of the POG include:

Clinicians/Individual members:

  • Kirsi Isoheranen (EWMA President), Finland
  • Sebastian Probst (EWMA Immediate Past President), Switzerland

Industry representatives from EWMA Corporate A Sponsors

  • 3M
  • Coloplast
  • ConvaTec
  • Debx Medical
  • Essity
  • Fidia Pharma
  • Lohmann & Rauscher
  • Mölnlycke Health Care
  • Polymem
  • Smith & Nephew
  • Urgo

Representatives from current EWMA Project sponsors are also invited to join the POG meetings. 

Previous projects of the EWMA Patient Outcome Group:

  • Wound Care MDR Course in Copenhagen 7 November 2019
    Read more 
  • National public awareness events: Advocacy event in Berlin, May 2016. The event was arranged in connection with the EWMA 2016 Conference in Bremen. 
    Read more
  • EWMA Study Recommendations - for clinical investigations in leg ulcers and wound care (Publ. 2014).
    Read more
  • EWMA Document on evidence and outcome measures in wound care (Publ. 2010).
    Read more